Rani Therapeutics Holdings, Inc.
For the period ended Dec 31, 2024. Filed Mar 31, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 31, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Signatures
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
| Rani Therapeutics Holdings, Inc. | ||
| Date: March 31, 2025 | By: | /s/ Talat Imran |
|---|---|---|
| Talat Imran | ||
| Chief Executive Officer | ||
| (Principal Executive Officer) | ||
KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Talat Imran and Svai Sanford, and each of them, his true and lawful attorneys-in-fact, each with full power of substitution, for him in any and all capacities, to sign any amendments to this Annual Report on Form 10-K and to file the same, with exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, hereby ratifying and confirming all that each of said attorneys-in-fact or their substitute or substitutes may do or cause to be done by virtue hereof.
Pursuant to the requirements of the Securities Exchange Act of 1934, this Annual Report on Form 10-K has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.
| Signature | Title | Date |
|---|---|---|
| /s/ Talat Imran | Chief Executive Officer and Director | March 31, 2025 |
| Talat Imran | (Principal Executive Officer) | |
| /s/ Svai Sanford | Chief Financial Officer | March 31, 2025 |
| Svai Sanford | (Principal Financial and Accounting Officer) | |
| /s/ Mir Imran | Chairman of the Board | March 31, 2025 |
| Mir Imran | ||
| /s/ Dennis Ausiello | Director | March 31, 2025 |
| Dennis Ausiello | ||
| /s/ Jean-Luc Butel | Director | March 31, 2025 |
| Jean-Luc Butel | ||
| /s/ Laureen DeBuono | Director | March 31, 2025 |
| Laureen DeBuono | ||
| /s/ Andrew Farquharson | Director | March 31, 2025 |
| Andrew Farquharson | ||
| /s/ Maulik Nanavaty | Director | March 31, 2025 |
| Maulik Nanavaty | ||
| /s/ Lisa Rometty | Director | March 31, 2025 |
| Lisa Rometty | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.